Morris explains in “Buffett and Munger Unscripted: Three Decades of Investment and Business Insights from the Berkshire Hathaway Annual Shareholder Meetings” (Harriman House). “Much of what ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

On Wednesday, Miller was asked how it felt to face his old team in the AFC playoffs ... “I love those guys,” Miller said. “I love everything about the Denver Broncos.

BYD remains a compelling investment due to its double-digit sales growth, focus on competitive pricing, and strong profit margins, partly aided by the recent market pullback. The same has been ...